Hydrated rhabdophane with a general formula REEPO 4 •nH 2 O (REE: La → Dy) has been always considered to crystallize in the hexagonal system. A recent re-examination of this system by the use of synchrotron powder data of the SmPO 4 •0.667 H 2 O compound led to a structure crystallizing in the monoclinic C2 space group with a = 28.0903(1) Å, b = 6.9466(1) Å, c = 12.0304(1) Å, β = 115.23(1)°, and V = 2123.4 (1) Å 3 with 24 formula units per unit cell. The structure consists of infinite channels oriented along the [101] direction and formed by the connection of Sm-polyhedra and P-tetrahedra by sharing O-edges. The water molecules filling the space have been localized for the first time. The monoclinic form of the hydrated rhabdophane was confirmed by studying the series with REE: La → Dy. Moreover, the dehydration of SmPO 4 •0.667H 2 O led to the stabilization of an anhydrous form SmPO 4 in the C2 space group with a = 12.14426 (1) Å, b = 7.01776(1) Å, c = 6.34755(1) Å, β = 90.02 (1)°, V = 540.97(1) Å 3 , and Z = 6.
Several CeO(2)-based mixed oxides with general composition Ce(1-x)Ln(x)O(2-x/2) (for 0 ≤ x ≤ 1 and Ln = La, Nd, Sm, Eu, Gd, Dy, Er, or Yb) were prepared using an initial oxalic precipitation leading to a homogeneous distribution of cations in the oxides. After characterization of the Ce/Nd oxalate precursors and then thermal conversion to oxides at T = 1000 °C, investigation of the crystalline structure of these oxides was carried out by XRD and μ-Raman spectroscopy. Typical fluorite Fm ̅3m structure was obtained for relatively low Ln(III) contents, while a cubic Ia ̅3̅ superstructure was evidenced above x ≈ 0.4. Moreover, since Nd(2)O(3) does not crystallize with the Ia ̅3̅-type structure, two-phase systems composed with additional hexagonal Nd(2)O(3) were obtained for x(Nd) ≥ 0.73 in the Ce(1-x)Nd(x)O(2-x/2) series. The effect of heat treatment temperature on these limits was explored through μ-Raman spectroscopy, which allowed determining the presence of small amounts of the different crystal structures observed. In addition, the variation of the Ce(1-x)Ln(x)O(2-x/2) unit cell parameter was found to follow a quadratic relation as a result of the combination between increasing cationic radius, modifications of cation coordination, and decreasing O-O repulsion caused by oxygen vacancies.
The chemistry of thorium phosphate reported in the literature has
been found to be
erroneous. It was reconsidered in terms of careful chemical
preparations and specific
analytical methods. Special attention has been paid to the atom
ratio value referred to r =
thorium/phosphorus, which was experimentally fixed in order to obtain
the correct composition of the final compound. A new compound with the chemical
formula
Th4(PO4)4P2O7,
derived from the crystal structure determination, has been obtained.
The unit cell
parameters were obtained from powder and single-crystal X-ray
diffraction data. It is
orthorhombic (space group Pcam, Z = 2) with the
cell dimensions a = 12.8646(9) Å, b
=
10.4374(8) Å, c = 7.0676(5) Å, and V
= 949.00(9) Å3. The atomic positions were
derived
from Patterson and Fourier methods and the structure was refined to an
R value of 0.039.
The structure consists of layers parallel to (010) containing both
PO4 and P2O7 groups.
These
layers alternate with planes of Th atoms. The coordination sphere
of the two independent
heavy atoms is formed by eight O atoms from five PO4 and
one P2O7 groups. The formula
of thorium phosphate
Th4(PO4)4P2O7
is in good agreement with the elementary composition
derived from electron microprobe analysis, which gave a ratio
r = 2/3. Any other value of
r
(1/2 < r <
3/4) induces the formation of polyphase
systems: Th4P6O23 and ThO2
for r > 2/3;
Th4P6O23 and
ThP2O7 for r <
2/3. The characterization of thorium
phosphate diphosphate by
means of infrared spectroscopy confirmed the presence of diphosphate
groups in the
compound.
On the basis of optimized grinding/heating cycles developed for several phosphate-based ceramics, the preparation of brabantite and then monazite/brabantite solid solutions loaded with tetravalent thorium, uranium, and cerium (as a plutonium surrogate) was examined versus the heating temperature. The chemical reactions and transformations occurring when heating the initial mixtures of AnO2/CeO2, CaHPO(4).2H2O (or CaO), and NH4H2PO4 were identified through X-ray diffraction (XRD) and thermogravimetric/differential thermal analysis experiments. The incorporation of thorium, which presents only one stabilized oxidation state, occurs at 1100 degrees C. At this temperature, all the thorium-brabantite samples appear to be pure and single phase as suggested by XRD, electron probe microanalyses, and micro-Raman spectroscopy. By the same method, tetravalent uranium can be also stabilized in uranium-brabantite, i.e., Ca0.5U0.5PO4, after heating at 1200 degrees C. Both brabantites, Ca0.5Th0.5PO4 and Ca0.5U0.5PO4, begin to decompose when increasing the temperature to 1400 and 1300 degrees C, respectively, leading to a mixture of CaO and AnO2 by the volatilization of P4O10. In contrast to the cases of thorium and uranium, cerium(IV) is not stabilized during the heating treatment at high temperature. Indeed, the formation of Ca0.5Ce0.5PO4 appears impossible, due to the partial reduction of cerium(IV) into cerium(III) above 840 degrees C. Consequently, the systems always appear polyphase, with compositions of CeIII1-2xCeIVxCaxPO4 and Ca2P2O7. The same conclusion can be also given when discussing the incorporation of cerium(IV) into La1-2xCeIIIx-yCeIVyCay(PO4)1-x+y. This incomplete incorporation of cerium(IV) confirms the results obtained when trying to stabilize tetravalent plutonium in Ca0.5PuIV0.5PO4 samples.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.